Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma, Inc. - Common Stock (NQ: ALBO )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Albireo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results. 
Via Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Okyo Pharma Ltd. ADR (NASDAQ: OKYO) gained 30% to $5.20 as the company priced its IPO at $4 per ADS. 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Walmart Earnings Miss Estimates
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. 
Via Benzinga
Albireo Pharma: Q1 Earnings Insights
Albireo Pharma (NASDAQ:ALBO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Albireo Pharma missed estimated... 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Albireo Pharma's Earnings Outlook
Albireo Pharma (NASDAQ:ALBO) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Albireo Pharma... 
Via Benzinga
Albireo Pharma Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Albireo Pharma (NASDAQ:ALBO) reported Q4 sales of $32.52 million. Earnings fell to a loss of $10.96 million, resulting in a 119.2% decrease from last quarter.... 
Via Benzinga
Recap: Albireo Pharma Q4 Earnings
Albireo Pharma (NASDAQ:ALBO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63... 
Via Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout... 
Via Benzinga
Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript
ALBO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Albireo Pharma Sells Bylvay-Associated PRV For $105M
Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus... 
Via Benzinga
Exposures Product Safety
Looking into Albireo Pharma's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Albireo Pharma (NASDAQ:ALBO) posted sales of $2.43 million. Earnings were up 16.96%, but Albireo Pharma still... 
Via Benzinga
Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript
ALBO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat... 
Via Benzinga
Exposures Product Safety
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic... 
Via Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study
Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of... 
Via Benzinga
Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc... 
Via Benzinga
Albireo Pharma, Inc. (ALBO) Q1 2021 Earnings Call Transcript
ALBO earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.